Table 1: Demographic, anthropometric, laboratory and patientsí disease SLE in crossover study before starting treatment and placebo.

Characteristics

Mean (N = 29)

Range

Standard deviation

Age (years)

33.66

20-54

8.60

Ilness duration (months)

93.83

6-296

72.62

Age of diagnosis

25.83

17-48

7.67

Education (years)

10.41

4-17

3.15

Number of medications in use

3.21

1-7

1.61

SLICC

0.36

0-5

0.98

SLEDAI

3.85

0-10

3.09

DNA damage index (%)

43.38

29.50-60.50

7.08

BMI (kg/m2)

24.05

17.26-43.70

5.51

Waist circumference (cm)

88.82

73.50-135

13.71

Hip circumference (cm)

98.91

82-139

10.55

Waist-hip ratio

0.87

0.79-0.87

0.048

Adequacy AC (%)

101.18%

80.06-146.85

13.35

Adequacy TS (%)

109.26

58.82-204.44

30.87

Adequacy AMC(%)

100.04

88.34-129.95

9.24

Hemoglobin g/dl

13.29

11.6-15.10

0.87

Creatinine mg/dL

0.65

0.5-1.0

0.095

Complement C3 mg/dL

96.18

52.9-159

26.44

Complement C4 mg/dL

16.74

3.70-42.60

7.83

Total cholesterol mg/dL

167.61

116-219

25.23

Triglycerides mg/dL

113.11

50-251

45.90

HDL mg/dL

45.50

22-69

11.41

LDL mg/dL

99.49

60.40-147.20

22.97

VLDL mg/dL

22.61

10-50

9.16

Albumin g/dL

4.20

3.80-4.90

0.25

hs-CRP mg/dL

0.30

0.09-1.5

0.32

 

SLICC: Systemic Lupus International Collaborating Clinics; SLEDAI: Systemic Lupus Erythematosus Disease Activity Index; BMI: Body Mass Index; AC: Arm Circumference;

TS: Triceps Skinfold; AMC: Arm Muscle Circumference; HDL: High-Density Lipoprotein; LDL: Low-Density Lipoprotein; VLDL: Very-Low-Density Lipoprotein; hs-CRP: high-sensitivity C-reactive protein (hs-CRP).